Unlocking the Potential of Antibody Drug Conjugates: Market Insights and Innovations https://www.marketsandmarkets.com/Market-Reports/antibody-drug-conjugates-market-122857391.html The antibody drug conjugates market is projected to reach USD 19.8 Billion by 2028 from USD 9.7 Billion in 2023, at a CAGR of 15.2% during the forecast period. Growth in the antibody drug conjugates market can be attributed to factors such as the collaborations and partnerships among market players for the development of new ADCs, and the rising number of government approvals for antibody drug conjugates. The global antibody drug conjugates market is highly competitive. The prominent players operating in this market include F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), and Zydus Group (India), among others.